A systematic study of molecular diagnosis, treatment, and prognosis in infant-type hemispheric glioma: an individual patient data meta-analysis of 164 patients
Due to the novelty and rarity of infant-type hemispheric glioma (IHG), optimal treatment and factors determining clinical outcomes are yet to be established.We curated a series of 164 patients with IHG; 155 identified by methodical literature search and nine additional patients contributed by collab...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2026
|
| In: |
Neuro-Oncology
Year: 2025, Pages: 1-14 |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/noaf264 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/neuonc/noaf264 |
| Verfasserangaben: | Lara Chavaz, Aditi Bagchi, Sandeep K. Dhanda, Fabienne Toutain, Stefan M. Pfister, Dominik Sturm, Torsten Pietsch, Gerrit H. Gielen, Andreas Waha, Matthew Clarke, Congyu Lu, Michael Karremann, Martin Benesch, Thomas Perwein, Gunther Nussbaumer, Christof Kramm, Maura Massimino, Veronica Biassoni, Maria Vinci, Angela Mastronuzzi, Dannis van Vuurden, Sophie E.M. Veldhuijzen van Zanten, Alan Mackay, Chris Jones, David T.W. Jones, Ana S. Guerreiro Stucklin, Uri Tabori, Cynthia Hawkins, Scott Ryall, Andrés Morales La Madrid, Alvaro Lassaletta, Simon Bailey, Darren Hargrave, Jason Chiang, Moatasem El-Ayadi, Bruna Minniti Mançano, Rui Manuel Reis, Christian Hagel, Hamza Gorsi, Nicolas Silvestrini, Ahmed Gilani, Ludmila Papusha, Paul Klimo Jr, Xin Zhou, Amar Gajjar, Giles W. Robinson, and Andre O. von Bueren |
| Zusammenfassung: | Due to the novelty and rarity of infant-type hemispheric glioma (IHG), optimal treatment and factors determining clinical outcomes are yet to be established.We curated a series of 164 patients with IHG; 155 identified by methodical literature search and nine additional patients contributed by collaborators.All tumors were hemispheric, diagnosed at a median age of 3.4 (0-52) months, and frequently (95%) non-metastatic. One hundred forty-two (86.5%) tumors harbored fusions involving receptor tyrosine kinase (RTK) genes (ALK [67/142, 47%], NTRK1/2/3 [32/142, 22.5%], ROS1 [29/142, 20.4%], MET [13/142, 9.2%], and ABL2 [1/142, 0.7%]). Sixty-four percentage, 20%, and 8% of patients were treated with surgery and adjuvant chemotherapy, surgery-only, and surgery plus targeted therapy, respectively. Five patients received radiation. Three-year event-free survival (EFS) and overall survival (OS) was 49.5% [40.7-60.2] and 79.6% [72.1-87.9], respectively. Twenty-two patients succumbed to disease, of which tumor progression (8/22, 36%) and intra-cranial hemorrhage (5/22, 23%) were the most common causes. Multivariate analysis showed that the factors most associated with an increased risk of death were no treatment except for surgery and presence of residual tumor after definitive surgery. These findings present a challenging dichotomy where surgery is both a serious risk factor for early death and, when successful, a benefit.Together, these findings show that IHG is a fusion driven tumor of the very young that is survivable even after progression. While optimal primary therapy for patients with IHG has yet to be established, the findings of this meta-analysis suggest treatment should focus on lowering surgical morbidity and improving its success. |
|---|---|
| Beschreibung: | Online veröffentlicht: 8. November 2025 Gesehen am 02.03.2026 |
| Beschreibung: | Online Resource |
| ISSN: | 1523-5866 |
| DOI: | 10.1093/neuonc/noaf264 |